Phase II Study of Optimized Management of NIVOlumab Based on REsponse in Patients With Advanced Renal Cell Carcinoma (OMNIVORE Study)
Phase of Trial: Phase II
Latest Information Update: 18 Jul 2018
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms OMNIVORE Study
- 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 10 Oct 2017 Status changed from not yet recruiting to recruiting.
- 01 Aug 2017 Planned initiation date changed from 30 Jun 2017 to 15 Aug 2017.